Yarrow Bioscience, Inc. (YARW) stock
YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30102% above fair value
$14.21+0.28 (+2.01%)
Close on Nov 17, 2026Market cap $37.94MP/E –Yield –
Yarrow Bioscience cash
Cash and short-term investments held at the end of each period.
Yarrow Bioscience's cash was $22.93M at Jun 30, 2026. For fiscal 2025 it was $29.01M, down 52.8% from the year before. Over ten years it grew -4.0% a year on average. The highest annual figure on record is $136.25M in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.01M | -52.8% |
| FY2024 | Dec 31, 2024 | $61.52M | -34.1% |
| FY2023 | Dec 31, 2023 | $93.31M | +201.0% |
| FY2022 | Dec 31, 2022 | $31.00M | -27.7% |
| FY2021 | Dec 31, 2021 | $42.90M | -27.8% |
| FY2020 | Dec 31, 2020 | $59.40M | -3.0% |
| FY2019 | Dec 31, 2019 | $61.26M | -55.0% |
| FY2018 | Dec 31, 2018 | $136.25M | +108.0% |
| FY2017 | Dec 31, 2017 | $65.50M | +111.9% |
| FY2016 | Dec 31, 2016 | $30.91M | -29.4% |
| FY2015 | Dec 31, 2015 | $43.81M | +15946.9% |
| FY2014 | Dec 31, 2014 | $273.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.93M | -54.4% |
| Q1 FY2026 | Mar 31, 2026 | $24.93M | -59.5% |
| Q4 FY2025 | Dec 31, 2025 | $29.01M | -58.7% |
| Q2 FY2025 | Jun 30, 2025 | $39.65M | -49.2% |
| Q1 FY2025 | Mar 31, 2025 | $50.27M | -41.5% |
| Q4 FY2024 | Dec 31, 2024 | $61.52M | -34.1% |
| Q3 FY2024 | Sep 30, 2024 | $70.19M | +354.3% |
| Q2 FY2024 | Jun 30, 2024 | $78.10M | +278.5% |
| Q1 FY2024 | Mar 31, 2024 | $85.95M | +184.5% |
| Q4 FY2023 | Dec 31, 2023 | $93.31M | +201.0% |
| Q3 FY2023 | Sep 30, 2023 | $15.45M | -56.5% |
| Q2 FY2023 | Jun 30, 2023 | $20.63M | -51.8% |
| Q1 FY2023 | Mar 31, 2023 | $30.21M | -40.9% |
| Q4 FY2022 | Dec 31, 2022 | $31.00M | -27.7% |
| Q3 FY2022 | Sep 30, 2022 | $35.51M | -32.9% |
| Q2 FY2022 | Jun 30, 2022 | $42.80M | -58.8% |
| Q1 FY2022 | Mar 31, 2022 | $51.10M | -57.6% |
| Q4 FY2021 | Dec 31, 2021 | $42.90M | -27.8% |
| Q3 FY2021 | Sep 30, 2021 | $52.90M | -31.2% |
| Q2 FY2021 | Jun 30, 2021 | $104.00M | +3.6% |
| Q1 FY2021 | Mar 31, 2021 | $120.40M | +45.6% |
| Q4 FY2020 | Dec 31, 2020 | $59.40M | -3.0% |
| Q3 FY2020 | Sep 30, 2020 | $76.90M | -21.2% |
| Q2 FY2020 | Jun 30, 2020 | $100.40M | -8.2% |
| Q1 FY2020 | Mar 31, 2020 | $82.70M | -31.9% |
| Q4 FY2019 | Dec 31, 2019 | $61.26M | -55.0% |
| Q3 FY2019 | Sep 30, 2019 | $97.65M | -36.0% |
| Q2 FY2019 | Jun 30, 2019 | $109.41M | -28.8% |
| Q1 FY2019 | Mar 31, 2019 | $121.52M | -22.0% |
| Q4 FY2018 | Dec 31, 2018 | $136.25M | +108.0% |
| Q3 FY2018 | Sep 30, 2018 | $152.66M | +920.6% |
| Q2 FY2018 | Jun 30, 2018 | $153.76M | +1046.1% |
| Q1 FY2018 | Mar 31, 2018 | $155.84M | +2484.8% |
| Q4 FY2017 | Dec 31, 2017 | $65.50M | +111.9% |
| Q3 FY2017 | Sep 30, 2017 | $14.96M | – |
| Q2 FY2017 | Jun 30, 2017 | $13.42M | – |
| Q1 FY2017 | Mar 31, 2017 | $6.03M | – |
| Q4 FY2016 | Dec 31, 2016 | $30.91M | – |
See a number that looks wrong?